2008-07-24 07:00:00
BioSante Featured on TheStreet.com TV
Stephen M. Simes, CEO, Highlights Development Program for LibiGel
“BioSante Seeks ‘Female
Viagra’ Breakthrough” Link Provided
LINCOLNSHIRE, Ill.–(EMWNews)–BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announces that its CEO,
Stephen M. Simes, was interviewed by the “TheStreet.com”
and featured on the “TheStreet.com”
website.
The interview can be viewed on “TheStreet.com”
website at: http://www.thestreet.com/video/10429991/index.html?puc=lhhome
Gregg Greenberg interviews Mr. Simes and discusses the development
program for LibiGel® (testosterone gel), the
market potential for the product, and partnering opportunities. BioSante
currently is conducting three Phase III clinical trials for LibiGel. In
a completed LibiGel Phase II clinical trial, LibiGel therapy resulted in
a 238 percent increase in the number of satisfying sexual events. Today
in the U.S. there is no FDA approved pharmaceutical product available
for the treatment of Female Sexual Dysfunction (FSD) or Hypoactive
Sexual Desire Disorder (HSDD) even though men have had several choices
for years. BioSante believes LibiGel may be the first FDA approved
treatment for FSD, specifically HSDD, in menopausal women in the U.S.
Additional information is available online at: www.biosantepharma.com.
About LibiGel®
LibiGel is a gel formulation of testosterone designed to be quickly
absorbed through the skin after application of a pea-sized dose of gel
on the upper arm, delivering testosterone to the bloodstream evenly over
time and in a non-invasive and painless manner. Though generally
characterized as a male hormone, testosterone also is present in women
and its deficiency has been found to decrease libido or sex drive. In
addition, studies have shown that testosterone therapy can increase bone
density, raise energy levels and improve mood, in addition to boosting
sexual desire and activity.
According to a study published in the Journal of the American Medical
Association, 43 percent of American women (about 40 million) experience
some degree of impaired sexual function. Among the more than 1,400 women
surveyed, 32 percent lacked interest in sex and 26 percent could not
experience orgasm. According to IMS data, 2.0 million testosterone
prescriptions were written off-label for women by U.S. physicians in
2007. The majority of women with FSD are postmenopausal, experiencing
FSD due to hormonal changes following menopause, whether natural or
surgical.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health, menopause, contraception and male
hypogonadism. BioSante’s lead products include LibiGel®
(transdermal testosterone gel) in Phase III clinical development by
BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special
Protocol Assessment) for the treatment of female sexual dysfunction
(FSD), and Elestrin™ (estradiol gel)
developed through FDA approval by BioSante, indicated for the treatment
of moderate-to-severe vasomotor symptoms associated with menopause,
currently marketed in the U.S. Also in development are Bio-T-Gel™,
a testosterone gel for male hypogonadism, and an oral contraceptive in
Phase II clinical development using BioSante patented technology. The
current market in the U.S. for estrogen and testosterone products is
approximately $2.5 billion and for oral contraceptives approximately $3
billion. The company also is developing its calcium phosphate technology
(CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™).
Additional information is available online at: www.biosantepharma.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this news release that are
not historical in nature, particularly those that utilize terminology
such as “will,” ”potential”,
“could,” “can,”
”intends,” “continue,”
“plans,” “expects”
or comparable terminology, are forward-looking statements. Examples of
forward-looking statements in this news release include statements
regarding the expected timing of the initiation of clinical trials and
the submission of regulatory applications. Forward-looking
statements are based on current expectations and assumptions, and entail
various risks and uncertainties that could cause actual results to
differ materially from those expressed in such forward-looking
statements. Important factors known to BioSante that could cause actual
results to differ materially from those expressed in such
forward-looking statements include the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals and
achieving market acceptance, the success of clinical testing, and other
factors identified and discussed from time to time in BioSante’s filings
with the Securities and Exchange Commission, including those factors
discussed in BioSante’s most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q, which discussions also are
incorporated herein by reference. All forward-looking statements speak
only as of the date of this news release. BioSante undertakes no
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
|
McKinney/Chicago Relations: S. Holdsworth / Erica Ruderman Colontrelle / Janet Vasquez |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
